Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas

Brain Pathology

Volumn 21, Issue 5, 2011, Pages 564-574

  Horbinski, Craig ^a   Kofler, Julia ^b   Yeaney, Gabrielle ^c   Camelo Piragua, Sandra ^d   Venneti, Sriram ^e   Louis, David N ^d   Perry, Arie ^f   Murdoch, Geoffrey ^b   Nikiforova, Marina ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ganglioglioma; glioneuronal; isocitrate dehydrogenase

Indexed keywords

ISOCITRATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER GRADING; COHORT ANALYSIS; DEATH; DIFFERENTIAL DIAGNOSIS; ENZYME ANALYSIS; FEMALE; GENE MUTATION; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK; TUMOR DIAGNOSIS; TUMOR RECURRENCE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GANGLIOGLIOMA; GLIOMA; HUMANS; INFANT; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 80052022841     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00480.x     Document Type: Article

References (46)

1. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al, (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116: 2122-2126.
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A, (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
3. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al, (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
4. Brennan RL, Prediger DJ, (1981) Coefficient Kappa: some uses, misuses, and alternatives. Educ Psychol Meas 41: 687-699.
5. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL, (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119: 509-511.
6. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, et al, (2009) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254.
7. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A, (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601.
8. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, et al, (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121: 241-252.
9. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al, (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
10. El Khashab M, Gargan L, Margraf L, Koral K, Nejat F, Swift D, et al, (2009) Predictors of tumor progression among children with gangliogliomas. Clinical article. J Neurosurg Pediatr 3: 461-466.
11. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, et al, (2010) Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95: 1274-1278.
12. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al, (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207: 339-344.
13. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al, (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
14. Hirose T, Scheithauer BW, Lopes MB, Gerber HA, Altermatt HJ, VandenBerg SR, (1997) Ganglioglioma: an ultrastructural and immunohistochemical study. Cancer 79: 989-1003.
15. Hoischen A, Ehrler M, Fassunke J, Simon M, Baudis M, Landwehr C, et al, (2008) Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol 18: 326-337. (Pubitemid 351782840)
16. Horbinski C, Hamilton RL, Lovell C, Burnham J, Pollack IF, (2009) Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol 20: 581-588.
17. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN, (2009) Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68: 1319-1325.
18. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF, (2010) Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 119: 641-649.
19. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN, (2010) Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12: 487-492.
20. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP, (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347.
21. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al, (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353-355.
22. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, et al, (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118: 401-405.
23. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, et al, (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74: 1886-1890.
24. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (2007) WHO classification of tumors of the central nervous system. In: World Health Organization Classification of Tumors, H Ohgaki, (ed.), pp. 103-105. IARC: Lyon.
25. Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J, (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101: 146-155. (Pubitemid 38812434)
26. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M, (2008) Tumor recurrence and malignant progression of gangliogliomas. Cancer 113: 3355-3363.
27. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al, (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28: 2348-2355.
28. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al, (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
29. Murugan AK, Bojdani E, Xing M, (2010) Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393: 555-559.
30. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H, (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
31. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al, (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
32. Park SW, Chung NG, Han JY, Eom HS, Lee JY, Yoo NJ, Lee SH, (2009) Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer 125: 2485-2486.
33. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al, (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
34. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM, (2002) Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 61: 947-955. (Pubitemid 35278716)
35. Perry A, Burton SS, Fuller GN, Robinson CA, Palmer CA, Resch L, et al, (2010) Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall. Acta Neuropathol 120: 237-252.
36. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, Laframboise WA, et al, (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 27: 87-94.
37. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, et al, (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100: 1996-1998.
38. Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D, et al, (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116: 614-616.
39. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, et al, (2011) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 128: 1095-1103.
40. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al, (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
41. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
42. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al, (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750.
43. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al, (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880.
44. Wierzba-Bobrowicz T, Schmidt-Sidor B, Gwiazda E, Bertrand E, (1999) The significance of immunocytochemical markers, synaptophysin and neurofilaments in diagnosis of ganglioglioma. Folia Neuropathol 37: 157-161.
45. Wolf HK, Muller MB, Spanle M, Zentner J, Schramm J, Wiestler OD, (1994) Ganglioglioma: a detailed histopathological and immunohistochemical analysis of 61 cases. Acta Neuropathol 88: 166-173. (Pubitemid 24233248)
46. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al, (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.